The tweet was deleted by the author.
But we saved everything 🙂.
Nurix Therapeutics announced the presentation of new preclinical and Phase 1 translational data focused on its investigational therapy, bexobrutideg (NX-5948), for chronic spontaneous urticaria (CSU) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting.
The presented data aim to demonstrate the potential of NX-5948 in addressing unmet needs for CSU patients, reflecting Nurix Therapeutics' ongoing commitment to advancing research in immunological disorders. More information about the presentation and data can be found on the company’s official resources.
Nurix Therapeutics previously announced plans to share updated Phase 1a b data for its BTK degrader NX-5948 in chronic lymphocytic leukemia at the EHA2026 in June 2026. The company has focused development of NX-5948 across multiple indications. Recent data presentations highlight Nurix's research activity in both immunological and hematological disorders.